Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced the appointment of Adrienne
L. Graves, Ph.D., to its Board of Directors.
A visual scientist by training and a global industry leader in
ophthalmology, Dr. Graves brings extensive experience to her role.
As the former CEO of Santen Inc., the US subsidiary of a
130-year-old Japanese pharmaceutical company, she successfully
established a strong global presence, bringing multiple ophthalmic
products through development to approval and commercialization and
leading global teams through successful acquisitions and
partnerships.
“Dr. Graves is a recognized and respected leader in
ophthalmology with a proven track record of leading global teams at
vision companies, and we are thrilled to welcome her to our team,”
said Antony Mattessich, President and CEO, Ocular Therapeutix. “We
look forward to benefitting from her insights and expertise as we
continue to drive the company’s growth and move our pipeline
forward.”
At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical
Development (US, Europe, and Japan) for seven years and
subsequently as CEO for eight years. Prior to Santen, she spent 9
years at Alcon, joining as Senior Scientist to establish Alcon’s
first Retinal Electrophysiology Laboratory. She progressed through
roles of increasing responsibility in research and development,
including directing clinical development in multiple therapeutic
areas and serving as Director of International Ophthalmology.
Dr. Graves currently serves as a director on the boards of
Greenbrook TMS Inc.; Qlaris Bio, Inc.; Nicox S.A.; NVasc, Inc.;
Surface Ophthalmics, Inc.; and Opus Genetics, Inc. She previously
served as Chairman of the Board of IVERIC bio, Inc. and held board
positions at TherOptix, Inc.; Encore Vision, Inc.; Envisia
Therapeutics, Inc.; Oxurion NV; TearLab Corporation (now Trukera
Medical); Aerpio Therapeutics, Inc.; and Akorn, Inc.
She serves on the Foundation Boards of the American Society of
Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma
Research Foundation, American Academy of Ophthalmology Foundation
(Emeritus), Retina Global, Himalayan Cataract Project, Foundation
Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund.
Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World
Leaders, formerly Ophthalmic Women Leaders).
Dr. Graves received an A.B. with Honors in Psychology from Brown
University, a Ph.D. in Psychobiology from the University of
Michigan, and she completed a Postdoctoral Fellowship in Visual
Neuroscience at the University of Paris. She is a Visionary
Innovation Mentor at the Ophthalmic Innovation Program at Stanford
University.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and diabetic retinopathy;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
Forward Looking Statements
Any statements in this press release about future expectations,
plans, and prospects for the Company, including the
commercialization of DEXTENZA® or any of the Company’s products or
product candidates; the development and regulatory status of the
Company’s product candidates; the potential utility of any of the
Company’s product candidates; the sufficiency of the Company’s cash
resources; and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Such
forward-looking statements involve substantial risks and
uncertainties that could cause the Company’s preclinical and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the timing and costs involved
in commercializing DEXTENZA or any product or product candidate
that receives regulatory approval, including the conduct of
post-approval studies, the ability to retain regulatory approval of
DEXTENZA or any product or product candidate that receives
regulatory approval, the ability to maintain and the sufficiency of
product, procedure and any other reimbursement codes for DEXTENZA,
the initiation, timing, conduct and outcomes of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific
approach and general development progress, the sufficiency of cash
resources, the Company’s existing indebtedness, the ability of the
Company’s creditors to accelerate the maturity of such indebtedness
upon the occurrence of certain events of default, the Company’s
ability to enter into strategic alliances or generate additional
funding on a timely basis, on favorable terms, or at all, the
Company’s ability to recruit and retain key personnel, and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with
the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so, whether as a result of new information, future events or
otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing the Company’s
views as of any date subsequent to the date of this press
release.
InvestorsOcular TherapeutixDonald NotmanChief
Financial Officerdnotman@ocutx.comorICR WestwickeChris Brinzey,
339-970-2843Managing Directorchris.brinzey@westwicke.com
MediaICR WestwickeBen Shannon,
443-213-0495ben.shannon@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024